Elicio Therapeutics (ELTX) Total Current Liabilities (2020 - 2026)
Elicio Therapeutics' (ELTX) quarterly Total Current Liabilities came in at $7.2 million in Q1 2026, down 36.66% YoY from $11.4 million in Q1 2025, and down 10.86% on a QoQ basis from $8.1 million in Q4 2025.
Elicio Therapeutics (ELTX) Total Current Liabilities (2020 - 2026) Analysis & Trends
Elicio Therapeutics (ELTX) has 7 years of Total Current Liabilities data on file, last reported at $7.2 million in Q1 2026.
- Quarterly Total Current Liabilities fell 36.66% year-over-year to $7.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.2 million (down 36.66% YoY) and the FY2025 annual result came in at $8.1 million, down 29.62% from the prior year.
- Total Current Liabilities eased to $7.2 million in Q1 2026, from $8.1 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $11.5 million in Q4 2024 to a low of $2.0 million in Q1 2023.
- A 5-year average of $8.3 million and a median of $8.1 million in 2025 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2023 — Total Current Liabilities slumped 80.44% — and 2024, when it jumped 193.01%.
- Tracing ELTX's Total Current Liabilities over 5 years: stood at $6.9 million in 2022, then surged by 42.04% to $9.8 million in 2023, then gained by 18.12% to $11.5 million in 2024, then fell by 29.62% to $8.1 million in 2025, then fell by 10.86% to $7.2 million in 2026.
- The last three Total Current Liabilities figures came in at $7.2 million (Q1 2026), $8.1 million (Q4 2025), and $6.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | Elicio Therapeutics | 58.41 Mn | 34.91 Mn | - | 9.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.20 Mn |
| Mar 31, 2026 | 7.23 Mn |
| Dec 31, 2025 | 8.11 Mn |
| Sep 30, 2025 | 6.52 Mn |
| Jun 30, 2025 | 9.92 Mn |
| Mar 31, 2025 | 11.41 Mn |
| Dec 31, 2024 | 11.52 Mn |
| Sep 30, 2024 | 9.02 Mn |
| Jun 30, 2024 | 7.59 Mn |
| Mar 31, 2024 | 5.95 Mn |
| Dec 31, 2023 | 9.76 Mn |
| Sep 30, 2023 | 11.49 Mn |
| Jun 30, 2023 | 7.60 Mn |
| Mar 31, 2023 | 2.03 Mn |
| Dec 31, 2022 | 6.87 Mn |
| Sep 30, 2022 | 8.18 Mn |
| Jun 30, 2022 | 7.78 Mn |
| Mar 31, 2022 | 10.38 Mn |
| Dec 31, 2021 | 11.30 Mn |
| Sep 30, 2021 | 17.95 Mn |